marked.bio

anti-LAG-3 antibody · antibody

relatlimab

3 active trials across 2 of our biomarkers, targeting LAG-3. Not approved for any biomarker on marked.bio yet.

Also known as BMS-986016.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 2 4 Phase 2
BRAF V600E 1 1 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of relatlimab.

  1. Replimune 1

Trials

3 of 5 trials shown

  1. VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

    Recruiting Phase 3 Replimune Started 2024Primary completion 2030-09 NCT06264180

    Vusolimogene OderparepvecnivolumabrelatlimabpembrolizumabSingle-agent chemotherapy

    …apy must be the immediate prior line of treatment before randomization (for patients with BRAF mutation, see I 4).

    BRAF V600EAdvanced Melanoma

  2. Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

    Active, not recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2018Primary completion 2027-10 NCT03607890

    nivolumab FDA EUrelatlimab

    Have metastatic or locally advanced mismatch repair deficient/MSI-H disease.

    MSI-H / dMMRRefractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors

  3. Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

    Recruiting Phase 2 The Netherlands Cancer Institute Started 2017Primary completion 2032-03 NCT03026140

    nivolumab FDA EUipilimumab FDA EUCelecoxib 200mgBMS-986253relatlimab

    dMMR cohorts 3+6: \>cT3 and/or N+

    MSI-H / dMMRColon Carcinoma